Methotrexate (Pre-conception only)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.41 [0.59, 3.38]0%5 studies27,659214not evaluable ROB-
Major congenital malformations1.24 [0.45, 3.42]0%3 studies27,658210not evaluable ROB-
3 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Small for gestational age (weight)0.82 [0.27, 2.47]0%2 studies645not evaluable ROB-
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine death (< 22 weeks)0.55 [0.18, 1.70]73%3 studies138274not evaluable ROB-
Late intrauterine deaths (> 22 weeks)1.74 [0.27, 11.38]22%3 studies6274not evaluable ROB-
Therapeutic terminations of pregnancy1.42 [0.51, 3.97]0%3 studies22274not evaluable ROB-
Intrauterine deaths (as a whole or unspecified)0.37 [0.09, 1.53]74%2 studies57138not evaluable ROB-
Elective/induced termination of pregnancy2.40 [1.06, 5.42]-1 study62136not evaluable ROB4.23 [1.32; .]